These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 556989)

  • 1. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
    Lappalainen J; Hietala J; Syvälahti E
    Psychopharmacology (Berl); 1989; 98(4):472-5. PubMed ID: 2570432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants.
    Barnes DE; Robinson B; Csernansky JG; Bellows EP
    Pharmacol Biochem Behav; 1990 Aug; 36(4):883-7. PubMed ID: 2217518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment.
    Ushijima I; Mizuki Y; Yamada M
    Pharmacol Biochem Behav; 1995 Feb; 50(2):259-64. PubMed ID: 7740066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of age and isolation on the evolution of catalepsy during chronic haloperidol treatment.
    Frussa-Filho R; Otoboni JR; Uema FT; Palermo-Neto J
    Braz J Med Biol Res; 1992; 25(9):925-8. PubMed ID: 1342840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperprolactinemia and catalepsy induced by haloperidol].
    Reggio A; Condorelli DF; De Simone D; Giammona G; Maccagnano C; Panico AM; Tigano G
    Boll Soc Ital Biol Sper; 1981 Aug; 57(16):1655-9. PubMed ID: 7197982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
    Viyoch J; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2001 Sep; 298(3):964-9. PubMed ID: 11504791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance and reverse tolerance to haloperidol catalepsy induced by the difference of administration interval in mice.
    Masuda Y; Murai S; Itoh T
    Jpn J Pharmacol; 1982 Dec; 32(6):1186-8. PubMed ID: 6891727
    [No Abstract]   [Full Text] [Related]  

  • 10. [The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative--in experiments on mice].
    Shapovalova VO; Mykhaĭlov VS; Shapovalov VV
    Fiziol Zh (1994); 1999; 45(3):114-7. PubMed ID: 10439301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of haloperidol on changes in development of spontaneous catalepsy during subchronic injections of dopamine agonists and antagonists].
    Kozlovskiĭ VL
    Patol Fiziol Eksp Ter; 2012; (3):75-80. PubMed ID: 23072116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial 6-hydroxydopamine-induced lesions and haloperidol-induced catalepsy.
    Johnson SK; Fisher H; Wagner GC
    Neuropharmacology; 1993 Mar; 32(3):273-8. PubMed ID: 8474623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioned tolerance to haloperidol- and droperidol-induced catalepsy.
    Nowak K; Welsch-Kunze S; Kuschinsky K
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr; 337(4):385-91. PubMed ID: 3405313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.
    Scotti de Carolis A; Popoli P; Pezzola A; Sagratella S
    Arch Int Pharmacodyn Ther; 1991; 310():132-41. PubMed ID: 1685312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
    Banasikowski TJ; Beninger RJ
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1525-34. PubMed ID: 22093169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of piracetam, a cyclic GABA analogue, on haloperidol-induced catalepsy in the rat.
    Balsara JJ; Bapat TR; Chandorkar AG
    Indian J Physiol Pharmacol; 1980; 24(3):227-32. PubMed ID: 7193183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
    Mycroft FJ; Wei ET
    Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ontogeny of tolerance to haloperidol: behavioral and biochemical measures.
    Coyle S; Napier TC; Breese GR
    Brain Res; 1985 Nov; 355(1):27-38. PubMed ID: 4075104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol catalepsy in grouped and isolated mice.
    Zetler G
    Pharmacology; 1975; 13(6):526-32. PubMed ID: 1241136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol-induced tolerance to morphine catalepsy.
    Ezrin-Waters C; Seeman P
    Life Sci; 1977 Aug; 21(3):419-22. PubMed ID: 561283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.